相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Raghuveer Singh Mali et al.
HAEMATOLOGICA (2021)
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy
Bhagirathbhai Dholaria et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission
Yishai Ofran et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Richard T. Maziarz et al.
BONE MARROW TRANSPLANTATION (2021)
Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
Andreas Burchert
HAEMATOLOGICA (2021)
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Laura K. Schmalbrock et al.
BLOOD (2021)
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (vol 13, 132, 2020)
Musa Yilmaz et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
Christoph Roellig et al.
LEUKEMIA (2021)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Richard A. Larson et al.
LEUKEMIA (2021)
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
Abhishek Maiti et al.
BLOOD CANCER JOURNAL (2021)
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
Hagop M. Kantarjian et al.
CANCER (2021)
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
Mahesh Swaminathan et al.
HAEMATOLOGICA (2021)
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
Mike Dennis et al.
BLOOD ADVANCES (2021)
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
Sunil K. Joshi et al.
CANCER CELL (2021)
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
James D. Griffin et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Alexander E. Perl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
Lisa Kim et al.
CARDIO-ONCOLOGY (2021)
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
Naval Daver et al.
BLOOD CANCER JOURNAL (2021)
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W. Pratz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation
Fang Chen et al.
BONE MARROW TRANSPLANTATION (2020)
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Konstanze Doehner et al.
BLOOD (2020)
Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation
Grzegorz Helbig et al.
ANNALS OF HEMATOLOGY (2020)
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ali Bazarbachi et al.
HAEMATOLOGICA (2020)
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
Luke Fletcher et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up.
Alexander E. Perl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
Tomoya Aikawa et al.
Oncotarget (2020)
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
Ying Jin et al.
FRONTIERS IN PHARMACOLOGY (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Motoki Eguchi et al.
BIOMEDICINES (2020)
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan et al.
LANCET ONCOLOGY (2020)
Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
Mara W. Rosenberg et al.
Oncotarget (2020)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Maria Teresa Voso et al.
BLOOD ADVANCES (2020)
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
Eunice S. Wang et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations
Marina Konopleva et al.
BLOOD (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML
Mark Levis et al.
BLOOD ADVANCES (2020)
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736
Andrew S. Moore et al.
BLOOD ADVANCES (2020)
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party
Ali Bazarbachi et al.
HAEMATOLOGICA (2019)
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon et al.
CANCER DISCOVERY (2019)
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib
Fevzi Yalniz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
Koji Sasaki et al.
CANCER (2019)
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Jun Ma et al.
CLINICAL CANCER RESEARCH (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia
Shilpa Paul et al.
FUTURE ONCOLOGY (2019)
Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Selina M. Luger et al.
BLOOD (2019)
BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML
Mark J. Levis et al.
BLOOD (2019)
Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
Hussein A. Abbas et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML
Jorge E. Cortes et al.
BLOOD (2018)
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship
Tao Liu et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+(CD279+) lymphocytes in marrow
Andrzej Lange et al.
PLOS ONE (2018)
Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
Keith W. Pratz et al.
BLOOD (2018)
Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort
Jordi Esteve et al.
BLOOD (2018)
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
Jessica K. Altman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
Prajwal Boddu et al.
BLOOD ADVANCES (2017)
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation
Sameh Gaballa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
Anthony D. Ho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
Betul Oran et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/ Refractory Acute Myeloid Leukemia (R/R AML)
Alexander E. Perl et al.
BLOOD (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
Yi-Yu Ke et al.
SCIENTIFIC REPORTS (2015)
Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis
M. Port et al.
ANNALS OF HEMATOLOGY (2014)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
David C. Linch et al.
BLOOD (2014)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia
Mark Levis
FUTURE ONCOLOGY (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature
Jayastu Senapati et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2014)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kerstin Maria Kampa-Schittenhelm et al.
MOLECULAR CANCER (2013)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
Influence of FLT3-Internal Tandem Duplication Allele Burden and White Blood Cell Count on the Outcome in Patients With Intermediate-Risk Karyotype Acute Myeloid Leukemia
Jonathan How et al.
CANCER (2012)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
R. M. Stone et al.
LEUKEMIA (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML
Wei Li et al.
LEUKEMIA RESEARCH (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Molecular prognostic factors in cytogenetically normal acute myeloid leukemia
Alison Walker et al.
EXPERT REVIEW OF HEMATOLOGY (2012)
Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
Manish Sharma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia
Fabio P. S. Santos et al.
CANCER (2011)
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Gautam Borthakur et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD
Hendrik J. M. de Jonge et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications
Shinichiro Takahashi
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features
Pradeep S. Chauhan et al.
MEDICAL ONCOLOGY (2011)
Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model
Perry M. Chan
PROTEIN & CELL (2011)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway
David Kent et al.
CLINICAL CANCER RESEARCH (2008)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations
T. Odgerel et al.
ONCOGENE (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
Lars Mollgard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus-negative leukemia cell lines
Y. Furukawa et al.
LEUKEMIA (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
